Nicole H M K Uszko-Lencer1, Rafael Mesquita2, Eefje Janssen3, Christ Werter4, Hans-Peter Brunner-La Rocca5, Fabio Pitta6, Emiel F M Wouters2, Martijn A Spruit3. 1. Department of Research & Education, CIRO, Center of Expertise for Chronic Organ Failure, Horn, The Netherlands; Department of Cardiology, Maastricht University Medical Center+ (MUMC+), Maastricht, The Netherlands. Electronic address: n.lencer@mumc.nl. 2. Department of Research & Education, CIRO, Center of Expertise for Chronic Organ Failure, Horn, The Netherlands; Department of Respiratory Medicine, Maastricht University Medical Center+ (MUMC+), Maastricht, The Netherlands. 3. Department of Research & Education, CIRO, Center of Expertise for Chronic Organ Failure, Horn, The Netherlands. 4. Department of Cardiology, Laurentius Hospital, Roermond, The Netherlands. 5. Department of Cardiology, Maastricht University Medical Center+ (MUMC+), Maastricht, The Netherlands. 6. Laboratory of Research in Respiratory Physiotherapy, Department of Physiotherapy, State University of Londrina (UEL), Londrina, Brazil.
Abstract
BACKGROUND: In-depth analyses of the measurement properties of the 6-minute walk test (6MWT) in patients with chronic heart failure (CHF) are lacking. We investigated the reliability, construct validity, and determinants of the distance covered in the 6MWT (6MWD) in CHF patients. METHODS: 337 patients were studied (median age 65years, 70% male, ejection fraction 35%). Participants performed two 6MWTs on subsequent days. Demographics, anthropometrics, clinical data, ejection fraction, maximal exercise capacity, body composition, lung function, and symptoms of anxiety and depression were also assessed. Construct validity was assessed in terms of convergent, discriminant and known-groups validity. Stepwise linear regression was used. RESULTS: 6MWT was reliable (ICC=0.90, P<0.0001). The learning effect was 31m (95%CI 27, 35m). Older age (≥65years), lower lung diffusing capacity (<80% predicted) and higher NYHA class (NYHA III) were associated with a lower likelihood of a meaningful increase in the second test (OR 0.45-0.56, P<0.05 for all). The best 6MWD had moderate-to-good correlations with peak exercise capacity (rs=0.54-0.69) and no-to-fair correlations with body composition, lung function, ejection fraction, and symptoms of anxiety and depression (rs=0.04-0.49). Patients with higher NYHA classes had lower 6MWD. 6MWD was independently associated with maximal power output during maximal exercise, estimated glomerular filtration rate and age (51.7% of the variability). CONCLUSION: 6MWT was found to be reliable and valid in patients with mild-to-moderate CHF. Maximal exercise capacity, renal function and age were significant determinants of the best 6MWD. These findings strengthen the clinical utility of the 6MWT in CHF.
BACKGROUND: In-depth analyses of the measurement properties of the 6-minute walk test (6MWT) in patients with chronic heart failure (CHF) are lacking. We investigated the reliability, construct validity, and determinants of the distance covered in the 6MWT (6MWD) in CHFpatients. METHODS: 337 patients were studied (median age 65years, 70% male, ejection fraction 35%). Participants performed two 6MWTs on subsequent days. Demographics, anthropometrics, clinical data, ejection fraction, maximal exercise capacity, body composition, lung function, and symptoms of anxiety and depression were also assessed. Construct validity was assessed in terms of convergent, discriminant and known-groups validity. Stepwise linear regression was used. RESULTS: 6MWT was reliable (ICC=0.90, P<0.0001). The learning effect was 31m (95%CI 27, 35m). Older age (≥65years), lower lung diffusing capacity (<80% predicted) and higher NYHA class (NYHA III) were associated with a lower likelihood of a meaningful increase in the second test (OR 0.45-0.56, P<0.05 for all). The best 6MWD had moderate-to-good correlations with peak exercise capacity (rs=0.54-0.69) and no-to-fair correlations with body composition, lung function, ejection fraction, and symptoms of anxiety and depression (rs=0.04-0.49). Patients with higher NYHA classes had lower 6MWD. 6MWD was independently associated with maximal power output during maximal exercise, estimated glomerular filtration rate and age (51.7% of the variability). CONCLUSION: 6MWT was found to be reliable and valid in patients with mild-to-moderate CHF. Maximal exercise capacity, renal function and age were significant determinants of the best 6MWD. These findings strengthen the clinical utility of the 6MWT in CHF.
Authors: Vitor H F Oliveira; Joseph D Perazzo; Richard A Josephson; Rafael Deminice; Allison R Webel Journal: J Assoc Nurses AIDS Care Date: 2018-06-04 Impact factor: 1.354
Authors: Karsten Vanden Wyngaert; Wim Van Biesen; Sunny Eloot; Amaryllis H Van Craenenbroeck; Patrick Calders; Els Holvoet Journal: PLoS One Date: 2022-05-19 Impact factor: 3.752
Authors: Beatriz Carpallo-Porcar; Laura Romo-Calvo; Sara Pérez-Palomares; Carolina Jiménez-Sánchez; Pablo Herrero; Natalia Brandín-de la Cruz; Sandra Calvo Journal: PLoS One Date: 2022-07-19 Impact factor: 3.752
Authors: Vivian Z Tan; Meredith Q Lee; Daryl L Wong; Katherin S Huang; Melissa Y Chan; Clement C Yan; Meredith T Yeung Journal: Hong Kong Physiother J Date: 2021-01-13
Authors: Karsten Vanden Wyngaert; Bert Celie; Patrick Calders; Sunny Eloot; Els Holvoet; Wim Van Biesen; Amaryllis H Van Craenenbroeck Journal: PLoS One Date: 2020-07-30 Impact factor: 3.240
Authors: Michael G Paulus; Christine Meindl; Lukas Böhm; Magdalena Holzapfel; Michael Hamerle; Christian Schach; Lars S Maier; Kurt Debl; Bernhard Unsöld; Christoph Birner Journal: PLoS One Date: 2020-05-28 Impact factor: 3.240